Nonselective proteasome inhibitors in multiple myeloma and future perspectives

References

• Allegra A, Alonci A, Gerace D, et al. New orally active proteasome inhibitors in multiple myeloma. Leuk Res. 2014;38(1):1–9.
   PubMedGoogle Scholar
• Ntanasis-Stathopoulos I, Gavriatopoulou M, Terpos E, et al. Real-world treatment of patients with relapsed/refractory myeloma. Clin Lymphoma Myeloma Leuk. 2021;21(6):379–385.
   PubMedGoogle Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5:e528
   PubMedGoogle Scholar
• Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105–e118.
   PubMed Web of Science ®Google Scholar
• Lois LM, Lima CD. Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. EMBO J. 2005;24(3):439–451.
   PubMed Web of Science ®Google Scholar
• Pickart CM, Cohen RE. Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol. 2004;5(3):177–187.
   PubMed Web of Science ®Google Scholar
• Demartino GN, Gillette TG. Proteasomes: machines for all reasons. Cell. 2007;129(4):659–662.
   PubMedGoogle Scholar
• Ferrell K, Wilkinson CR, Dubiel W, et al. Regulatory subunit interactions of the 26S proteasome, a complex problem. Trends Biochem Sci. 2000;25(2):83–88.
   PubMedGoogle Scholar
• Baumeister W, Walz J, Zuhl F, et al. The proteasome: paradigm of a self-compartmentalizing protease. Cell. 1998;92(3):367–380.
   PubMed Web of Science ®Google Scholar
• Goldberg AL, Cascio P, Saric T, et al. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol. 2002;39(3–4):147–164.
   PubMed Web of Science ®Google Scholar
• Weissman AM, Shabek N, Ciechanover A. The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat Rev Mol Cell Biol. 2011;12(9):605–620.
   PubMed Web of Science ®Google Scholar
• Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. Int J Mol Sci. 2021;22(9):4462.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Orlowski RZ. The immunoproteasome as a target in hematologic malignancies. Semin Hematol. 2012;49(3):258–262.
   PubMed Web of Science ®Google Scholar
• Merin NM, Kelly KR. Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharmaceuticals (Basel). 2014;8(1):1–20.
   PubMedGoogle Scholar
• Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14(7):417–433.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang X, Wang Y, et al. Inhibition of immunoproteasome reduces infarction volume and attenuates inflammatory reaction in a rat model of ischemic stroke. Cell Death Dis. 2015;6(1):e1626.
   PubMedGoogle Scholar
• Wojcik C, Di Napoli M. Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy. Stroke. 2004;35(6):1506–1518.
   PubMed Web of Science ®Google Scholar
• Meusser B, Hirsch C, Jarosch E, et al. ERAD: the long road to destruction. Nat Cell Biol. 2005;7(8):766–772.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol. 2006;46(1):189–213.
   PubMedGoogle Scholar
• Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today. 2010;15:243–249.
   PubMed Web of Science ®Google Scholar
• Crawford LJ, Walker B, Ovaa H, et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res. 2006;66:6379–6386.
   PubMed Web of Science ®Google Scholar
• Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett. 1998;8:333–338.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120(8):1589–1596.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519–527
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–1060.
   PubMed Web of Science ®Google Scholar
• Kane RC, Bross PF, Farrell AT, et al. Velcade: u.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8:508–513.
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101–5109.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745–4753.
   PubMed Web of Science ®Google Scholar
• Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115(16):3416–3417.
   PubMed Web of Science ®Google Scholar
• Terpos E, Zamagni E, Lentzsch S, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e119–e130.
   PubMedGoogle Scholar
• Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches. Blood. 2019;133(14):1534–1539.
   PubMed Web of Science ®Google Scholar
• Terpos E, Kastritis E, Ntanasis-Stathopoulos I, et al. Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: effects on survival and bone outcomes in the absence of bisphosphonates. Am J Hematol. 2019;94:400–407.
   PubMedGoogle Scholar
• Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719–734.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer J. 2017;7(6):e571.
   PubMedGoogle Scholar
• Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52–iv61.
   PubMed Web of Science ®Google Scholar
• Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, et al. Multiple myeloma: role of autologous transplantation. Cancer Treat Rev. 2020;82:101929.
   PubMed Web of Science ®Google Scholar
• Ntanasis-Stathopoulos I, Terpos E, Dimopoulos MA. Optimizing immunomodulatory drug with proteasome inhibitor combinations in newly diagnosed multiple myeloma. Cancer J. 2019;25(1):2–10.
   PubMed Web of Science ®Google Scholar
• Mai EK, Bertsch U, Durig J, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29(8):1721–1729.
   PubMed Web of Science ®Google Scholar
• Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016;127(21):2569–2574.
   PubMed Web of Science ®Google Scholar
• Einsele H, Knop S, Vogel M, et al. Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma. Leukemia. 2017;31(6):1463–1466.
   PubMed Web of Science ®Google Scholar
• Raedler L. Velcade (Bortezomib) receives 2 new FDA indications: for retreatment of patients with multiple myeloma and for first-line treatment of patients with mantle-cell lymphoma. Am Health Drug Benefits. 2015;8:135–140.
   PubMedGoogle Scholar
• Petrucci MT, Giraldo P, Corradini P, et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol. 2013;160(5):649–659.
   PubMed Web of Science ®Google Scholar
• Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13(1):27–46.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113–3120.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma. 2010;51(7):1178–1187.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol. 2007;204(1):317–325.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14(6):1649–1657.
   PubMed Web of Science ®Google Scholar
• Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383–6391.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281–3290.
   PubMed Web of Science ®Google Scholar
• Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753–1761.
   PubMed Web of Science ®Google Scholar
• Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17(9):2734–2743.
   PubMed Web of Science ®Google Scholar
• Herndon TM, Deisseroth A, Kaminskas E, et al. U.S. food and drug administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res. 2013;19(17):4559–4563.
   PubMed Web of Science ®Google Scholar
• Hajek R, Masszi T, Petrucci MT, et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017;31(1):107–114.
   PubMed Web of Science ®Google Scholar
• Hajek R, Bryce R, Ro S, et al. Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer. 2012;12(1):415.
   PubMedGoogle Scholar
• Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97(12):1925–1928.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108(10):3458–3464.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826–1832.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Bringhen S, Anttila P, et al. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood. 2021;137(9):1154–1165.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 2011;39(10):1873–1882.
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, Siegel DS, Vesole DH, et al. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol. 2015;33(7):732–739.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327–1337.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Moreau P, Dimopoulos MA, et al. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019;9(3):23.
   PubMed Web of Science ®Google Scholar
• Ailawadhi S, Sexton R, Lentzsch S, et al. Low-dose versus high-dose carfilzomib with dexamethasone (S1304) in patients with relapsed-refractory multiple myeloma. Clin Cancer Res. 2020;26(15):3969–3978.
   PubMedGoogle Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(8):728–734.
   PubMed Web of Science ®Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126(20):2284–2290.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Zweegman S, Cavo M, et al. Carfilzomib, pomalidomide and dexamethasone (KPd) in patients with multiple myeloma refractory to bortezomib and lenalidomide, the EMN011 trial. Blood. 2018;132(Supplement 1):801. Abstract 801.
   Google Scholar
• Berenson JR, Cartmell A, Bessudo A, et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016;127(26):3360–3368.
   PubMed Web of Science ®Google Scholar
• Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953–964.
   PubMed Web of Science ®Google Scholar
• Biran N, Siegel D, Berdeja JG, et al. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a phase 1b study. Am J Hematol. 2019;94(7):794–802.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Mina R, Cafro AM, et al. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia. 2018;32(8):1803–1807.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–197.
   PubMed Web of Science ®Google Scholar
• Moreau P, Dimopoulos M-A, Mikhael J, et al. Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multpile myeloma (IKEMA): interim analysis of a phase I randomized, open-label study. Paper presented at the European Hematology Association Virtual Meeting, 11–21 June 2020. Abstract LB2603.
   Google Scholar
• Mateos M-V, Ocio EM, Sureda Balari A, et al. Randomized phase 2 study of weekly carfilzomib 70 Mg/m2 and dexamethasone plus/minus cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) patients (GEM-KyCyDex). Blood. 2020;136(Supplement 1):8–9. Abstract 415.
   PubMedGoogle Scholar
• Gasparetto C, Lipe B, Tuchman SA, et al. Selinexor in combination with carfilzomib and dexamethasone, all once weekly (SKd), for patients with relapsed/refractory multiple myeloma. Blood. 2020;136(Supplement 1):14–15.
   Google Scholar
• Terpos E, Ntanasis-Stathopoulos I, Katodritou E, et al. Carfilzomib improves bone metabolism in patients with advanced Relapsed/Refractory Multiple Myeloma: results of the CarMMa study. Cancers (Basel). 2021;13. DOI:https://doi.org/10.3390/cancers13061257.
   Google Scholar
• Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, et al. Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. Blood Cancer J. 2020;10:25.
   PubMedGoogle Scholar
• Bringhen S, Milan A, Ferri C, et al. Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018;103(9):1422–1432.
   PubMed Web of Science ®Google Scholar
• Chen-Scarabelli C, Corsetti G, Pasini E, et al. Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity. EBioMedicine. 2017;21:206–212.
   PubMed Web of Science ®Google Scholar
• Efentakis P, Kremastiotis G, Varela A, et al. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019;133(7):710–723.
   PubMed Web of Science ®Google Scholar
• Shirley M. Ixazomib: first Global Approval. Drugs. 2016;76(3):405–411.
   PubMed Web of Science ®Google Scholar
• Tzogani K, Florez B, Markey G, et al. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open. 2019;4(5):e000570.
   PubMed Web of Science ®Google Scholar
• Zanwar S, Abeykoon JP, Kapoor P. Ixazomib: a novel drug for multiple myeloma. Expert Rev Hematol. 2018;11(10):761–771.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311–5321.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Kumar SK, Masszi T, et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2021:JCO2100972. DOI:https://doi.org/10.1200/JCO.21.00972
   Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Terpos E, Ramasamy K, Maouche N, et al. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Ann Hematol. 2020;99(5):1049–1061.
   PubMed Web of Science ®Google Scholar
• Li J, Bao L, Xia Z, et al. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Ann Hematol. 2020;99(11):2589–2598.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Berdeja JG, Niesvizky R, et al. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019;33(7):1736–1746.
   PubMed Web of Science ®Google Scholar
• Stege CAM, Nasserinejad K, Van Der Spek E, et al. Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the Hovon 143 study. J Clin Oncol. 2021;39(25):2758–2767.
   PubMed Web of Science ®Google Scholar
• Zweegman S, Stege CAM, Haukas E, et al. Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica. 2020;105:2879–2882.
   PubMedGoogle Scholar
• Fotiou D, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Multiple myeloma: current and future management in the aging population. Maturitas. 2020;138:8–13.
   PubMedGoogle Scholar
• Gavriatopoulou M, Fotiou D, Koloventzou U, et al. Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leuk Lymphoma. 2019;60(3):619–628.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, et al. How I treat elderly patients with plasma cell dyscrasias. Aging (Albany NY). 2018;10(12):4248–4268.
   PubMedGoogle Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–1791.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–1781.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905.
   PubMed Web of Science ®Google Scholar
• Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel). 2020;12(2):265.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019;393(10168):253–264.
   PubMed Web of Science ®Google Scholar
• Kaiser M, Beksac M, Gulbrandsen N, et al. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Ann Hematol. 2020;99(8):1793–1804.
   PubMedGoogle Scholar
• Goldschmidt H, Dimopoulos MA, Rajkumar SV, et al. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia. 2020;34(11):3019–3027.
   PubMed Web of Science ®Google Scholar
• Terpos E, Ntanasis-Stathopoulos I, International Myeloma S. Clinical updates regarding multiple myeloma from the 2019 American Society of Hematology Annual Meeting. Clin Lymphoma Myeloma Leuk. 2020;20(8):499–508.
   PubMed Web of Science ®Google Scholar
• Vij R, Martin TG I, Nathwani N. Ixazomib or lenalidomide maintenance following autologous stem cell transplantation and ixazomib, lenalidomide, and dexamethasone (IRD) consolidation in patients with newly diagnosed multiple myeloma: results from a large multi-center randomized phase II trial. Blood. 2019;134:602.
   Google Scholar
• Dimopoulos MA, Spicka I, Quach H, et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial. J Clin Oncol. 2020;38(34):4030–4041.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol. 2016;34(4):381–386.
   PubMed Web of Science ®Google Scholar
• Groll M, Potts BC. Proteasome structure, function, and lessons learned from beta-lactone inhibitors. Curr Top Med Chem. 2011;11(23):2850–2878.
   PubMedGoogle Scholar
• Lawasut P, Chauhan D, Laubach J, et al. New proteasome inhibitors in myeloma. Curr Hematol Malig Rep. 2012;7(4):258–266.
   PubMedGoogle Scholar
• Feling RH, Buchanan GO, Mincer TJ, et al. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl. 2003;42(3):355–357.
   PubMed Web of Science ®Google Scholar
• Cusack JC Jr., Liu R, Xia L, et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res. 2006;12(22):6758–6764.
   PubMedGoogle Scholar
• Appel A. Drugs: more shots on target. Nature. 2011;480(7377):S40–42.
   PubMedGoogle Scholar
• Zhou HJ, Aujay MA, Bennett MK, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem. 2009;52(9):3028–3038.
   PubMed Web of Science ®Google Scholar
• Haselbach D, Schrader J, Lambrecht F, et al. Long-range allosteric regulation of the human 26S proteasome by 20S proteasome-targeting cancer drugs. Nat Commun. 2017;8(1):15578.
   PubMedGoogle Scholar
• Infante JR, Mendelson DS, Burris HA 3rd, et al. A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. Invest New Drugs. 2016;34(2):216–224.
   PubMed Web of Science ®Google Scholar
• Hari P, Paba-Prada CE, Voorhees PM, et al. Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Leuk Res. 2019;83:106172.
   PubMedGoogle Scholar
• Shah J, Usmani S, Stadtmauer EA, et al. Oprozomib, pomalidomide, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(9):570–578 e571.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Vij R, Siegel D, et al. A phase Ib/II study of oprozomib in patients with advanced multiple myeloma and waldenstrom macroglobulinemia. Clin Cancer Res. 2019;25(16):4907–4916.
   PubMed Web of Science ®Google Scholar
• Piva R, Ruggeri B, Williams M, et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008;111(5):2765–2775.
   PubMed Web of Science ®Google Scholar
• Zang Y, Thomas SM, Chan ET, et al. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res. 2012;18(20):5639–5649.
   PubMed Web of Science ®Google Scholar
• Hurchla MA, Garcia-Gomez A, Hornick MC, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 2013;27(2):430–440.
   PubMed Web of Science ®Google Scholar
• Dorsey BD, Iqbal M, Chatterjee S, et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem. 2008;51(4):1068–1072.
   PubMed Web of Science ®Google Scholar
• Sala F, Marangon E, Bagnati R, et al. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study. J Mass Spectrom. 2010;45(11):1299–1305.
   PubMed Web of Science ®Google Scholar
• Gallerani E, Zucchetti M, Brunelli D, et al. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer. 2013;49(2):290–296.
   PubMed Web of Science ®Google Scholar
• Ettari R, Previti S, Bitto A, et al. Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases. Curr Med Chem. 2016;23(12):1217–1238.
   PubMedGoogle Scholar
• Di Giovanni C, Ettari R, Sarno S, et al. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening. Eur J Med Chem. 2016;121:578–591.
   PubMed Web of Science ®Google Scholar
• Scarbaci K, Troiano V, Micale N, et al. Identification of a new series of amides as non-covalent proteasome inhibitors. Eur J Med Chem. 2014;76:1–9.
   PubMed Web of Science ®Google Scholar
• Muchamuel T, Basler M, Aujay MA, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 2009;15(7):781–787.
   PubMed Web of Science ®Google Scholar
• Ichikawa HT, Conley T, Muchamuel T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum. 2012;64(2):493–503.
   PubMed Web of Science ®Google Scholar
• Singh AV, Bandi M, Aujay MA, et al. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol. 2011;152(2):155–163.
   PubMed Web of Science ®Google Scholar
• Brouwer AJ, Jonker A, Werkhoven P, et al. Peptido sulfonyl fluorides as new powerful proteasome inhibitors. J Med Chem. 2012;55(24):10995–11003.
   PubMed Web of Science ®Google Scholar
• Ho YK, Bargagna-Mohan P, Wehenkel M, et al. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol. 2007;14(4):419–430.
   PubMedGoogle Scholar
• Myung J, Kim KB, Lindsten K, et al. Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Mol Cell. 2001;7(2):411–420.
   PubMedGoogle Scholar
• Basler M, Lauer C, Moebius J, et al. Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation. J Immunol. 2012;189(4):1868–1877.
   PubMedGoogle Scholar
• Terpos E, Ntanasis-Stathopoulos I, Roussou M, et al. Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. Ann Hematol. 2020;99(6):1257–1264.
   PubMedGoogle Scholar
• Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma-A promising key to therapy. J Clin Med. 2021;10(18):4088.
   PubMedGoogle Scholar
• Malandrakis P, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. clinical utility of selinexor/dexamethasone in patients with relapsed or refractory multiple myeloma: a review of current evidence and patient selection. Onco Targets Ther. 2020;13:6405–6416.
   PubMed Web of Science ®Google Scholar